PET/CT is extremely useful for therapy response assessment due to its capacity to help distinguish between residual metabolicallactive tumor and areas of necrosis and fibrosis, thus identifying which of these patients have achieved satisfactory functional remission and which that needs further treatment. Detecting post-operative local recurrence of the tumour even before anatomic changes are visible on conventional imaging. The main drawbacks of PET/CT management of bronchogenic carcinoma include radiation exposure and high cost. The use of diagnostic contrast enhanced CT with PET/CT although it expose the patients for more radiation risks.